Mabion Past Earnings Performance

Past criteria checks 1/6

Mabion has been growing earnings at an average annual rate of 62.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 54.3% per year. Mabion's return on equity is 7.9%, and it has net margins of 9.2%.

Key information

62.3%

Earnings growth rate

63.1%

EPS growth rate

Biotechs Industry Growth56.3%
Revenue growth rate54.3%
Return on equity7.9%
Net Margin9.2%
Next Earnings Update25 Nov 2024

Recent past performance updates

Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 24
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Recent updates

Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 24
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth

Nov 28
Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts

Jun 02
Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts

Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?

Jul 09
Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?

Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News

Jun 04
Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News

Is Mabion (WSE:MAB) Using Too Much Debt?

Dec 22
Is Mabion (WSE:MAB) Using Too Much Debt?

Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

Sep 11
Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?

Feb 24
How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?

Revenue & Expenses Breakdown

How Mabion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:MAB Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411110532
30 Jun 2414037493
31 Mar 2414642425
31 Dec 2315241406
30 Sep 2314858398
30 Jun 23157423514
31 Mar 23165323115
31 Dec 22164232915
30 Sep 2215645348
30 Jun 2211734349
31 Mar 227526328
31 Dec 213623014
30 Sep 212-512128
30 Jun 212-452024
31 Mar 210-532030
31 Dec 200-561934
30 Sep 200-551736
30 Jun 200-631840
31 Mar 200-692143
31 Dec 190-642141
30 Sep 190-652240
30 Jun 190-592139
31 Mar 190-702045
31 Dec 180-692045
30 Sep 180-722348
30 Jun 180-742349
31 Mar 180-592241
31 Dec 170-582143
30 Sep 170-561843
30 Jun 170-571647
31 Mar 170-591547
31 Dec 160-561344
30 Sep 160-771171
30 Jun 160-65959
31 Mar 163-51848
31 Dec 153-43540
30 Sep 153-640
30 Jun 153-530
31 Mar 151-520
31 Dec 141-410
30 Sep 141-440
30 Jun 140-440
31 Mar 140-440
31 Dec 130-440

Quality Earnings: MAB has a large one-off loss of PLN13.3M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: MAB's current net profit margins (9.2%) are lower than last year (39.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 62.3% per year.

Accelerating Growth: MAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MAB had negative earnings growth (-82.4%) over the past year, making it difficult to compare to the Biotechs industry average (-20.8%).


Return on Equity

High ROE: MAB's Return on Equity (7.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies